- Home
- DLTH vs ABOS Comparison
DLTH vs ABOS Comparison
Compare DLTH & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLTH | ABOS |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.1M | 113.9M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DLTH | ABOS |
|---|---|---|
| Price | $2.36 | $1.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $7.67 |
| AVG Volume (30 Days) | 194.1K | ★ 212.6K |
| Earning Date | 12-16-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $590,561,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.86 |
| 52 Week High | $4.66 | $2.46 |
Technical Indicators
Market Signals| Indicator | DLTH | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.21 |
| Support Level | N/A | $1.67 |
| Resistance Level | N/A | $2.39 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 35.64 |
Price Performance
Historical ComparisonAbout DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.